Solutions

Selexis has developed proprietary protein expression tools that can be used with predictability and a high commitment to safety.

Selexis SA is a scientific pioneer and global leader in mammalian (suspension-adapted CHO-K1) cell line generation that has been setting the pace of innovation in protein expression and establishing new benchmarks in bioproduction for more than a decade.

Unleashing the power of novel protein therapeutics to transform the care of and prospects for millions of patients who suffer from life-threatening diseases depends heavily on continued advances in technologies and methods for protein expression. This is particularly critical for medicines that are based on recombinant proteins, such as monoclonal antibodies, and difficult-to-express proteins, including Fc-fusion proteins, bi-specific monoclonal antibodies, and novel scaffolds.